Ticker reaction data

ORION CORP NEW UNSP/ADR (ORINY)

ORINY moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How ORINY actually reacts to news — the realized, point-in-time move the market made, measured across 282 labeled events over the last three years with zero look-ahead.

The quantified answer

ORINY’s median reaction, across the day.

0.00%
Median 30-min
Typical reaction 30 minutes after any ORINY news
9%
Moved up
Share of ORINY news events that rose at 30 minutes
0.00%
Median to close
Where ORINY typically settles by the closing bell
ORINY median reaction to newsORINY median reaction to news across 4 horizons: 5-min +0.00%, 30-min +0.00%, 60-min +0.00%, to close +0.00%.5-min30-min60-minto close5-min: +0.00%30-min: +0.00%60-min: +0.00%to close: +0.00%+0.00%+0.00%+0.00%+0.00%0
Median move vs. the price at the news timestamp, each horizon on its own sample — the counts are in the table below.
ORINY median reaction to news, by horizon. Each rung is measured on the events that traded at that horizon.
HorizonMedian% positiveEvents
5-min0.00%9%86
30-min0.00%9%86
60-min0.00%11%86
to close0.00%22%87

Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.

Next time, know first

Email me when ORINY moves on news.

One email per qualifying move — the headline, the measured reaction, and how it compares to ORINY's baseline. Nothing else.

▲ ORINY Free · unsubscribe anytime
26M+ news records Operating since 2012 Methodology on SSRN ↗
Latest news

Recent ORINY events, each with its measured reaction.

DateHeadlineEventSource5-minTo close
Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual MeetingPress releaseGlobeNewswire——
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the futurePress releaseGlobeNewswire——
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)Press releaseGlobeNewswire——
CHMP recommends third indication for darolutamide for patients with advanced prostate cancerPress releaseGlobeNewswire+0.00%+0.00%
Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in TurkuPress releaseGlobeNewswire——
EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availabilityPress releaseGlobeNewswire+0.00%+0.00%
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbusterPress releaseGlobeNewswire——
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in OncologyPress releaseGlobeNewswire——
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancerPress releaseGlobeNewswire——
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpointPress releaseGlobeNewswire——
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate CancerPress releaseGlobeNewswire——
Orion is developing the Finnish life science industry in a unique collaboration projectPress releaseGlobeNewswire——
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208Press releaseGlobeNewswire——

Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ORINY section they belong to.

Keep exploring

Where else ORINY is measured.

ORINY earnings → · Analyst actions → · SEC filings →

Every ticker we measure the same way24

Apple (AAPL)

How AAPL actually reacts to news, measured.

NVIDIA (NVDA)

How NVDA actually reacts to news, measured.

Tesla (TSLA)

How TSLA actually reacts to news, measured.

Microsoft (MSFT)

How MSFT actually reacts to news, measured.

Advanced Micro Devices (AMD)

How AMD actually reacts to news, measured.

Amazon (AMZN)

How AMZN actually reacts to news, measured.

Alphabet (GOOG)

How GOOG actually reacts to news, measured.

Meta Platforms (META)

How META actually reacts to news, measured.

Broadcom (AVGO)

How AVGO actually reacts to news, measured.

JPMorgan Chase (JPM)

How JPM actually reacts to news, measured.

Visa (V)

How V actually reacts to news, measured.

Walmart (WMT)

How WMT actually reacts to news, measured.

Eli Lilly (LLY)

How LLY actually reacts to news, measured.

UnitedHealth Group (UNH)

How UNH actually reacts to news, measured.

Netflix (NFLX)

How NFLX actually reacts to news, measured.

Johnson & Johnson (JNJ)

How JNJ actually reacts to news, measured.

Exxon Mobil (XOM)

How XOM actually reacts to news, measured.

Home Depot (HD)

How HD actually reacts to news, measured.

Costco (COST)

How COST actually reacts to news, measured.

Mastercard (MA)

How MA actually reacts to news, measured.

Oracle (ORCL)

How ORCL actually reacts to news, measured.

Salesforce (CRM)

How CRM actually reacts to news, measured.

Bank of America (BAC)

How BAC actually reacts to news, measured.

Coca-Cola (KO)

How KO actually reacts to news, measured.

Walt Disney (DIS)

How DIS actually reacts to news, measured.

Browse all tickers

Every name we’ve measured, in one place.

Method

How the numbers are made.

How is ORION CORP NEW UNSP/ADR's median reaction calculated?

Every labeled ORINY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 282 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.

What counts as a positive reaction?

Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 9% of ORINY's measured events are up at 30 minutes; the rest close the window flat or negative.

How often is this page updated?

The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.

Does ORINY's past reaction predict its next one?

No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.

Stop guessing what the event means

You just saw one reaction.
There are 26 million more.

For investors

Know the next move, measured.

Ticker alerts with the realized reaction — not the headline spin.

Free · no credit card · unsubscribe anytime
For builders

The dataset, one command away.

claude mcp add news-quantified

Then ask Claude: “how does ORINY react to downgrades?” — or pull it raw via REST.

60-second signup on the NQ portal · 100 free credits/mo
26M+ news records, 2006–2026 Operating since 2012 Point-in-time, zero look-ahead Peer-reviewable methodology (SSRN) ↗